Drug
Afamitresgene Autoleucel
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | CAR-T or Cell Therapy |
| Group | CAR-T or Cell Therapy |
| Mechanism of Action | TCR-based therapy |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic (RT debulks, induces ICD/cGAS-STING, ↑antigen/MHC-I, enhances trafficking/persistence), not a DNA-level sensitizer (Minn et al., Lancet Oncology, 2019; Hauth et al., JAMA Oncology, 2021). No in-field radiosensitization of normal tissue; theoretical adverse event concerns are immune/inflammatory (enhanced cytokine release or local inflammation).
Data on this page refer exclusively to patients treated with
Afamitresgene Autoleucel combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
CAR-T or Cell Therapy group page.